RT Journal Article
SR Electronic
T1 Optimizing the COVID-19 Intervention Policy in Scotland and the Case for Testing and Tracing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.11.20128173
DO 10.1101/2020.06.11.20128173
A1 Grothey, Andreas
A1 Mckinnon, Ken
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128173.abstract
AB Unlike other European countries the UK has abandoned widespread testing and tracing of known SARS-CoV-2 carriers in mid-March. The reason given was that the pandemic was out of control and with wide community based spread it would not be possible to contain it by tracing any longer. Like other countries the UK has since relied on a lockdown as the main measure to contain the virus (or more precisely the reproduction number ℛ) at significant economic and social cost. It is clear that this level of lockdown cannot be sustained until a vaccine is available, yet it is not clear what an exit strategy would look like that avoids the danger of a second (or subsequent waves).In this paper we argue that, when used within a portfolio of intervention strategies, widespread testing and tracing leads to significant cost savings compared to using lockdown measures alone. While the effect is most pronounced if a large proportion of the infectious population can be identified and their contacts traced, under reasonable assumptions there are still significant savings even if the fraction of infectious people found by tracing is small.We also present a policy optimization model that finds, for given assumptions on the disease parameters, the best intervention strategy to contain the virus by varying the degree of tracing and lockdown measure (and vaccination once that option is available) over time. We run the model on data fitted to the published COVID-19 outbreak figures for Scotland. The model suggests an intervention strategy that keeps the number of COVID-19 deaths low using a combination of tracing and lockdown. This strategy would only require lockdown measures equivalent to a reduction of ℛ to about 1.8–2.0 if lockdown was used alone, at acceptable economic cost, while the model finds no such strategy without tracing enabled.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available and sources have been referenced in the manuscript.